1. Al-Ali A, Alkhawajah AA, Randhawa MA, Shaikh NA (2008) Oral and intraperitoneal LD50 of thymoquinone, an active principle of Nigella sativa, in mice and rats.J Ayub. Med Coll Abbottabad 20:25–27
2. Al-Amri AM, Bamosa AO (2009) Phase I safety and clinical activity study of Thymoquinone in patients with Advanced Refractory Malignant Disease. Shiraz E-Med J 10:107–111
3. Al-Malky HS, Al Harthi SE, Osman AM (2020) Major obstacles to doxorubicin therapy: cardiotoxicity and drug resistance. J Oncol Pharm Pract 26:434–444
4. Almajali B, Al-Jamal HAN, Taib WRW, Ismail I, Johan MF, Doolaanea AA et al (2021) Thymoquinone, as a Novel Therapeutic candidate of cancers. Pharmaceuticals 14:369. https://doi.org/10.3390/ph14040369
5. Anlar HG, Bacanli M (2020) Thymoquinone: the active compound of black seed (Nigella sativa). In: Preedy VR (ed) Pathology. Oxidative stress and dietary antioxidants. Academic, Cambridge, pp 369–378